TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32622346
Drug: Intensive BP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive BP therapy (<120/80 mm Hg)
Study: 32622346
Drug: Standard BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP therapy (<140/90 mm Hg)
Study: 32023922
Drug: Angelica Gigas
Normalized name: ANGELICA GIGAS ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angelica Gigas Nakai Extract (AGNE) 1 g/day (200 mg/dose) for 12 weeks
Study: 34688549
Drug: Photon radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photon radiation therapy (IMRT)
Study: 33302644
Drug: Fan-zhen Jie-ci
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan-zhen Jie-ci (FZJC) acupuncture therapy
Study: 32144927
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture treatment
Study: 32107266
Drug: SPIOMET treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPIOMET treatment (low-dose combination of spironolactone, pioglitazone, and metformin)
Study: 32107266
Drug: Oral contraception-based
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception-based treatment
Study: 33091857
Drug: Propolis oral
Normalized name: propolis Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis oral spray (2-4 sprays three times/day for five days, total polyphenol content 15 mg/ml)
Study: 33091857
Drug: Propolis oral
Normalized name: propolis Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis oral spray
Study: 34750839
Drug: Rocuronium 12.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 12.0 μg·kg‐1 ·min‐1
Study: 34750839
Drug: Rocuronium 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 6.0 μg·kg‐1 ·min‐1
Study: 34750839
Drug: Rocuronium 9.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 9.0 μg·kg‐1 ·min‐1
Study: 34750839
Drug: Rocuronium 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 6.0 μg·kg‐1 ·min‐1 and 9.0 μg·kg‐1 ·min‐1
Study: 35177299
Drug: Pfizer vaccine
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer vaccine
Study: 37379532
Drug: AstraZeneca vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AstraZeneca vaccine
Study: 36249252
Drug: Sinopharm vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinopharm vaccine
Study: 32648393
Drug: Waiting for
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting for treatment group
Study: 35451469
Drug: 3.2 g
Normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g of magnesium daily (4 tablets of 0.4 g each twice daily) for 72 hours preoperatively and 1.6 g of magnesium on the day of surgery
Study: 32636239
Drug: TMBRB predicting
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMBRB predicting immunotherapy efficacy.
Study: 33481482
Drug: Simulated sunlight
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated sunlight (1.3× standard erythemal dose, three times per week for 4 weeks and then once per week for 8 weeks)
Study: 33481482
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (1000 IU·d‐1 for 4 weeks and then 400 IU·d‐1 for 8 weeks)
Study: 33370477
Drug: third-party bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: third-party bone marrow-derived MSC infusion
Study: 32534731
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid strategy (10 mL.kg‐1.h‐1 following institutional standard care protocol)
Study: 33905827
Drug: Lavandula angustifolia
Normalized name: Lavandula Angustifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavandula angustifolia essential oil inhalation for 29 days
Study: 33905827
Drug: Placebo (sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sunflower oil) inhalation for 29 days
Study: 36397215
Drug: Sham electroacupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroacupuncture at non-acupoints with shallow needling, no current, same treatment duration as EA group.
Study: 35592490
Drug: Duloxetine (10-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (10-week treatment)
Study: 35592490
Drug: Desvenlafaxine (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (12-week treatment)
Study: 32846775
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy Exercises (PTE)
Study: 32846775
Drug: Wharton Jelly
Normalized name: Human Umbilical Cord Wharton's Jelly-derived Mesenchymal Stem Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wharton Jelly mesenchymal stem cell (WJ‐MSCs) injections
Study: 32203712
Drug: Palivizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab (15 mg/kg, intramuscular injections during RSV season)
Study: 36370176
Drug: Collagen peptides
Normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen peptides (CP) 10 g·day‐1
Study: 33470341
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg codeine and 500 mg acetaminophen (4 times a day for 4 days)
Study: 32717180
Drug: Second-look surgery
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-look surgery plus oxaliplatin-HIPEC (oxaliplatin 460 mg/m2, or oxaliplatin 300 mg/m2 plus irinotecan 200 mg/m2, plus intravenous fluorouracil 400 mg/m2)
Study: 34584543
Drug: MIXTIVA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MIXTIVA infusion (remifentanil/propofol at a proportion of 2/1,000 or 3/1,000)
Study: 34584543
Drug: Standard TIVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TIVA with separate remifentanil and propofol infusions (Control Group I)
Study: 34584543
Drug: MIXTIVA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MIXTIVA infusion (Group III with remifentanil concentration 30 µg/ml)
Study: 34584543
Drug: MIXTIVA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MIXTIVA infusion (Group II with remifentanil concentration 20 µg/ml)
Study: 34084153
Drug: CDCA 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA 1.25 g
Study: 34084153
Drug: CDCA 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA 1.25 g + colesevelam 3.75 g
Study: 34084153
Drug: CDCA 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA 1.25 g (with mixed meal)
Study: 34084153
Drug: colesevelam 3.75
Normalized name: colesevelam 3.75 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: colesevelam 3.75 g (with mixed meal)
Study: 34084153
Drug: colesevelam 3.75
Normalized name: colesevelam 3.75 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: colesevelam 3.75 g × 2 (with mixed meal)
Study: 32308366
Drug: N-butylphthalide (NBP)
Normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-butylphthalide (NBP) and dexamethasone (DXM) combined with hyperbaric oxygen (HBO) therapy
Study: 32308366
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy as monotherapy (Control)
Study: 32197629
Drug: NEMEX-TJR twice
Normalized name: Nemex
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEMEX-TJR twice weekly for 12 weeks combined with two sessions of PNE
Study: 33549019
Drug: Yinxieling tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinxieling tablets
Study: 33570017
Drug: D-cycloserine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (250 mg)
Study: 33389761
Drug: Nano-curcumin (Sinacurcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (Sinacurcumin soft gel, 40 mg curcuminoids as nanomicelles, two capsules twice a day)
Study: 35938937
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Dolichos biflorus seeds (1,600 mg)
Study: 35938937
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Cynodon dactylon rhizome (1,600 mg)
Study: 34362522
Drug: Astaxanthin (ASTA)
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (ASTA) at concentrations of 5, 10, and 20 μmol/L
Study: 36498603
Drug: 3D adjustable
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D adjustable posture corrective orthotic (PCO) added to a multimodal program; performed mirror image therapy for 20–30 min while walking on a treadmill 2–3 times per week for 10 weeks.
Study: 32950989
Drug: Nasal device
Normalized name: Benzedrex, 250 mg nasal device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal device (soft silicone insert) for 5-12 hours daily
Study: 36653409
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg × 3 times/day)
Study: 34360105
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g serving
Study: 32843084
Drug: Fire needle
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needle therapy
Study: 33834343
Drug: Tomato cultivars
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato cultivars with 3.6 mg kg‐1 Cd
Study: 33834343
Drug: Tomato cultivars
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato cultivars with 12 mg kg‐1 Cd
Study: 33834343
Drug: Tomato cultivars
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato cultivars with long-term exposure to 12 mg kg‐1 Cd
Study: 35000893
Drug: Experimental formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formula (EF) with higher protein level of 3.4 g/100 kcal and improved fat blend
Study: 35000893
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula (CF) with protein level of 2.9 g/100 kcal and standard fat blend
Study: 33116455
Drug: Icenticaftor 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icenticaftor 300 mg b.i.d.
Study: 32005992
Drug: Immediate iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate iron treatment (ferrous sulfate 2 mg · kg‐1 · d‐1 for 3 months)
Study: 32005992
Drug: Delayed iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed iron treatment (ferrous sulfate 2 mg · kg‐1 · d‐1 for 3 months, starting 28 days after antimalarial treatment)
Study: 32705319
Drug: Peri-articular infiltration
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular infiltration of morphine, ropivacaine, and epinephrine
Study: 32855225
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP) - 84 mg (3 capsules once daily)
Study: 32855225
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP) - 140 mg (5 capsules once daily)
Study: 32855225
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP) - 224 mg (4 capsules twice daily)
Study: 32855225
Drug: Overall TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall TIP (all doses)
Study: 35238960
Drug: Ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 5 mg twice daily for 3 months
Study: 34031056
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg orally once daily)
Study: 34031056
Drug: Afatinib +
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib + Cetuximab (Cetuximab 250 mg/m² on day 15 of cycle 1, then every 2 weeks at 500 mg/m² for 6 months)
Study: 32807092
Drug: Short-duration antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-duration antibiotic therapy (7 days) after catheter removal
Study: 32807092
Drug: Long-duration antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-duration antibiotic therapy (≥14 days)
Study: 33293152
Drug: Vasopressor administration
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressor administration (N = 16)
Study: 33293152
Drug: No vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vasopressor administration (N = 36)
Study: 33293152
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin C (HDVC) administration
Study: 33293152
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin (Alb) administration
Study: 33291053
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (P‐PN) including lipid emulsion (17% SMOFlipid® lipid)
Study: 33080839
Drug: Weekly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly high-dose oral vitamin D supplementation
Study: 33080839
Drug: Daily high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily high-dose oral vitamin D supplementation
Study: 34498980
Drug: Dapivirine Gel
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine Gel (0.05%)
Study: 35925745
Drug: Supportive Treatment
Normalized name: Performax Salt Supportive Cream Base for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Treatment (ST)
Study: 34078324
Drug: Supportive-Expressive Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-Expressive Treatment (SET)
Study: 34385241
Drug: Enzalutamide monotherapy
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide monotherapy
Study: 33028197
Drug: Sufentanil (TCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (TCI Cet 0.48 ng ml‐1)
Study: 35183892
Drug: Prostacyclin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin infusion (1 ng/kg/min)
Study: 35183892
Drug: Prostacyclin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin infusion and Placebo
Study: 35144596
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg/qd)
Study: 35144596
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg/bid)
Study: 34275768
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg once a day for 6 months
Study: 38114794
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplementation
Study: 35438179
Drug: Oral CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CBD
Study: 35438179
Drug: Epidiolex (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidiolex (oral formulation)
Study: 35438179
Drug: Capsule (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule (oral formulation)
Study: 35438179
Drug: Syrup (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup (oral formulation)
Study: 35363951
Drug: Active-treatment group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-treatment group (antihypertensive medications recommended for use in pregnancy)
Study: 35363951
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment unless severe hypertension developed)
Study: 35363951
Drug: Active-treatment group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-treatment group
Study: 33711180
Drug: Felcisetrag 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felcisetrag 0.1 mg
Study: 33711180
Drug: Felcisetrag 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felcisetrag 0.3 mg
Study: 33711180
Drug: Felcisetrag 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felcisetrag 1.0 mg
Study: 33711180
Drug: Felcisetrag (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felcisetrag (all doses)
Study: 36126241
Drug: Evobrutinib 25
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 25 mg once-daily (q.d.)
Study: 36126241
Drug: Evobrutinib 75
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 75 mg once-daily (q.d.)
Study: 36126241
Drug: Evobrutinib 75
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 75 mg twice-daily (b.i.d.)
Study: 36126241
Drug: Evobrutinib 45
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 45 mg twice-daily (b.i.d.) with food
Study: 35819090
Drug: Suspension Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension Training System (STS)
Study: 35422023
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) including citalopram, paroxetine, and sertraline
Study: 35253598
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg + Gentian Violet
Study: 34258468
Drug: Propolis 500
Normalized name: propolis 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis 500 mg twice a day for 3 months
Study: 34258468
Drug: Placebo 500
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg twice a day for 3 months
Study: 32690834
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (topical + systemic, 800 mg/day)
Study: 32690834
Drug: Curcumin (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (topical + systemic, 950 mg/day)
Study: 32690834
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (green tea extract + curcumin)
Study: 36339547
Drug: Alfentanil (10–25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (10–25 μg/kg) combined with a fixed low dose of midazolam
Study: 36339547
Drug: Midazolam (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (fixed low dose)
Study: 32125434
Drug: MenACWY-Conjugate vaccine
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MenACWY-Conjugate vaccine
Study: 32125434
Drug: MenACWY-Polysaccharide vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-Polysaccharide vaccine
Study: 32125434
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (MenACWY-Conjugate and MenACWY-Polysaccharide)
Study: 34873992
Drug: Plyometric Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plyometric Training (PT) - two weekly sessions for eight weeks
Study: 34974559
Drug: Instrument-assisted soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrument-assisted soft tissue mobilization along with routine physical therapy
Study: 34974559
Drug: Both techniques
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both techniques (Instrument-assisted soft tissue mobilization and Routine physical therapy)
Study: 34013559
Drug: Adlerian therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adlerian therapy (AT)
Study: 33118194
Drug: PPE 25
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PPE 25 mg/kg body weight
Study: 33118194
Drug: PPE 50
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PPE 50 mg/kg body weight
Study: 33118194
Drug: PPE treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPE treatments (both doses)
Study: 36336899
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation
Study: 35877104
Drug: Disease-Modifying Treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-Modifying Treatments (DMTs)
Study: 34358723
Drug: Extra-Virgin Olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-Virgin Olive Oil (EVOO) 25 mL/d for 52 days
Study: 34358723
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (control) 25 mL/d for 52 days
Study: 32520410
Drug: SAR247799 (2.5–37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR247799 (2.5–37.5 mg single dose)
Study: 32520410
Drug: SAR247799 (0.5–15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR247799 (0.5–15 mg once-daily for 2 weeks)
Study: 32520410
Drug: SAR247799 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR247799 (10 mg)
Study: 32520410
Drug: SAR247799 (≤5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR247799 (≤5 mg)
Study: 35699623
Drug: MEDI0562 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0562 + durvalumab (7.5 mg MEDI0562 + 1,500 mg durvalumab)
Study: 35699623
Drug: MEDI0562 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0562 + tremelimumab (22.5 mg MEDI0562 + 225 mg tremelimumab)
Study: 34822784
Drug: HTL9936, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL9936, a muscarinic M1 receptor agonist, designed for cognitive loss in Alzheimer's disease.